한글목차

전신홍반루푸스의 동향과 예측

세계의 전신홍반루푸스 시장은 2024-2030년의 CAGR이 6.6%로, 2030년까지 추정 28억 달러에 달할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 자가면역질환의 이환율 증가, 염증성 자가면역질환에 대한 일반 시민의 의식 향상, 세계의 노인 인구의 증가입니다. 세계의 전신홍반루푸스 시장의 미래는 소매 약국, 병원, 온라인 약국의 각 시장에서의 비즈니스 기회에 의해 유망시되고 있습니다.

전신홍반루푸스 시장 인사이트

• Lucintel의 예측에서는 경구약이 투여가 용이한 저분자 약제를 포함하여 SLE의 치료제로서 일반적으로 사용되고 있으므로 환자 선호도가 높아지고 있으며, 예측 기간 중에도 최대 부문으로 유지될 것으로 생각됩니다.
• 이 시장에서 병원은 처방된 의약품을 구입하는 시설로서 선호도가 높아지고 있는 것으로 인해 예측 기간 중에도 최대 부문으로 유지될 것으로 생각됩니다.
• 북미는 강고한 헬스케어 인프라가 존재하고, 주요 기업이 진출하고 있는 것으로 인해 앞으로도 최대 지역입니다.

아래 11개의 주요 질문에 답변하고 있습니다. :

• Q.1.시장 부문 중 가장 유망하고 고성장인 기회는 무엇인가?
• Q.2.어느 부문이 보다 빠른 페이스로 성장하는가, 또 이유는?
• Q.3.향후 성장이 가속할 것으로 생각되는 지역과 이유는?
• Q.4.시장 역학에 영향을 미치는 주요 요인은 무엇인가? 시장에서 주요 과제와 비즈니스 리스크는?
• Q.5.이 시장에서 비즈니스 리스크와 경쟁의 위협은?
• Q.6.이 시장에서 새로운 동향과 이유는?
• Q.7.시장에서 고객의 수요 변화에는 어떤 것이 있는가?
• Q.8.이 시장에서 새로운 개발과 개발을 선도하고 있는 기업은?
• Q.9.이 시장의 주요 기업은? 주요 기업은 사업 성장을 위해 어떤 전략적 구상을 진행시키고 있는가?
• Q.10.이 시장에서 경쟁 제품에는 어떤 것이 있으며, 재료 및 제품의 대체에 의한 시장 점유율 저하의 위협은 어느 정도 있는가?
• Q.11.과거 5년간 어떤 M&A가 시행되고, 업계에 어떤 영향을 미쳤는가?

목차

제1장 주요 요약

제2장 세계의 전신홍반루푸스 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 2018-2030년의 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 전신홍반루푸스 시장 동향(2018-2023)과 예측(2024-2030)
• 약제 클래스별 세계의 전신홍반루푸스 시장
  • NSAID
  • 항말라리아약
  • 코르티코스테로이드
  • 면역억제제
  • 생물제제
• 투여 경로별 세계의 전신홍반루푸스 시장
  • 오랄
  • 정맥내
  • 피하
• 최종 용도별 세계의 전신홍반루푸스 시장
  • 소매 약국
  • 병원
  • 온라인 약국
  • 기타

제4장 2018-2030년의 지역별 시장 동향과 예측 분석

• 지역별 세계의 전신홍반루푸스 시장
• 북미의 전신홍반루푸스 시장
• 유럽의 전신홍반루푸스 시장
• 아시아태평양 전신홍반루푸스 시장
• 기타 지역의 전신홍반루푸스 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 약제 클래스별 세계의 전신홍반루푸스 시장의 성장 기회
  • 투여 경로별 세계의 전신홍반루푸스 시장의 성장 기회
  • 최종 용도별 세계의 전신홍반루푸스 시장의 성장 기회
  • 지역별 세계의 전신홍반루푸스 시장의 성장 기회
• 세계의 전신홍반루푸스 시장의 새로운 동향
• 전략적 분석
  • 신제품의 개발
  • 세계의 전신홍반루푸스 시장의 능력 확대
  • 세계의 전신홍반루푸스 시장에서의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 유력 기업의 기업 개요

• Roche
• Sanofi
• GlaxoSmithKline
• Pfizer
• Bayer
• Astra Zeneca
• Novartis

영문목차

Systemic Lupus Erythematosus Trends and Forecast

The future of the global systemic lupus erythematosus market looks promising with opportunities in the retail pharmacy, hospital, and online pharmacy markets. The global systemic lupus erythematosus market is expected to reach an estimated $2.8 billion by 2030 with a CAGR of 6.6% from 2024 to 2030. The major drivers for this market are increasing incidence of autoimmune diseases, rising public awareness regarding inflammatory autoimmune disorders, and growing number of geriatric population in worldwide.

A more than 150-page report is developed to help in your business decisions.

Systemic Lupus Erythematosus by Segment

The study includes a forecast for the global systemic lupus erythematosus by drug class, route of administration, end use, and region.

Systemic Lupus Erythematosus Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

• NSAIDs
• Antimalarials
• Corticosteroids
• Immunosuppressants
• Biologics

Systemic Lupus Erythematosus Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

• Oral
• Intravenous
• Subcutaneous

Systemic Lupus Erythematosus Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Retail Pharmacies
• Hospitals
• Online Pharmacies
• Others

Systemic Lupus Erythematosus Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Systemic Lupus Erythematosus Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies systemic lupus erythematosus companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the systemic lupus erythematosus companies profiled in this report include-

• Roche
• Sanofi
• GlaxoSmithKline
• Pfizer
• Bayer
• Astra Zeneca
• Novartis

Systemic Lupus Erythematosus Market Insights

• Lucintel forecasts that oral will remain the largest segment over the forecast period due to its growing preference among patients as it includes small molecule medications that are easy to administer and remains commonly used treatment for SLE.

• Within this market, hospital will remain the largest segment over the forecast period due to growing preference for this facility to purchase prescribed drugs.

• North America Will remain the largest region due to existence of robust healthcare infrastructure and presence of key players in the region.

Features of the Global Systemic Lupus Erythematosus Market

• Market Size Estimates: Systemic lupus erythematosus market size estimation in terms of value ($B).

• Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

• Segmentation Analysis: Systemic lupus erythematosus market size by drug class, route of administration, end use, and region. in terms of value ($B).

• Regional Analysis: Systemic lupus erythematosus market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

• Growth Opportunities: Analysis of growth opportunities in different drug classes, route of administrations, end uses, and region.s for the systemic lupus erythematosus market.

• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the systemic lupus erythematosus market.

• Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the systemic lupus erythematosus market size?

Answer: The global systemic lupus erythematosus market is expected to reach an estimated $2.8 billion by 2030.

Q.2. What is the growth forecast for systemic lupus erythematosus market?

Answer: The global systemic lupus erythematosus market is expected to grow with a CAGR of 6.6% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the systemic lupus erythematosus market?

Answer: The major drivers for this market are increasing incidence of autoimmune diseases, rising public awareness regarding inflammatory autoimmune disorders, and growing number of geriatric population in worldwide.

Q.4. What are the major segments for systemic lupus erythematosus market?

Answer: The future of the systemic lupus erythematosus market looks promising with opportunities in the retail pharmacy, hospital, and online pharmacy markets.

Q.5. Who are the key systemic lupus erythematosus market companies?

Answer: Some of the key systemic lupus erythematosus companies are as follows:

• Roche
• Sanofi
• GlaxoSmithKline
• Pfizer
• Bayer
• Astra Zeneca
• Novartis

Q.6. Which systemic lupus erythematosus market segment will be the largest in future?

Answer: Lucintel forecasts that oral will remain the largest segment over the forecast period due to its growing preference among patients as it includes small molecule medications that are easy to administer and remains commonly used treatment for SLE.

Q.7. In systemic lupus erythematosus market, which region is expected to be the largest in next 5 years?

Answer: North America Will remain the largest region due to existence of robust healthcare infrastructure and presence of key players in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the systemic lupus erythematosus market by drug class (NSAIDs, antimalarials, and corticosteroids, immunosuppressants, and biologics), route of administration (oral, intravenous, and subcutaneous), end use (retail pharmacies, hospitals, online pharmacies, and others)and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Systemic Lupus Erythematosus Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Systemic Lupus Erythematosus Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Systemic Lupus Erythematosus Market by Drug Class
  • 3.3.1: NSAIDs
  • 3.3.2: Antimalarials
  • 3.3.3: Corticosteroids
  • 3.3.4: Immunosuppressants
  • 3.3.5: Biologics
• 3.4: Global Systemic Lupus Erythematosus Market by Route of Administration
  • 3.4.1: Oral
  • 3.4.2: Intravenous
  • 3.4.3: Subcutaneous
• 3.5: Global Systemic Lupus Erythematosus Market by End Use
  • 3.5.1: Retail Pharmacies
  • 3.5.2: Hospitals
  • 3.5.3: Online Pharmacies
  • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Systemic Lupus Erythematosus Market by Region
• 4.2: North American Systemic Lupus Erythematosus Market
  • 4.2.1: North American Systemic Lupus Erythematosus Market by Route of Administration: Oral, Intravenous, and Subcutaneous
  • 4.2.2: North American Systemic Lupus Erythematosus Market by End Use: Retail Pharmacies, Hospitals, Online Pharmacies, and Others
• 4.3: European Systemic Lupus Erythematosus Market
  • 4.3.1: European Systemic Lupus Erythematosus Market by Route of Administration: Oral, Intravenous, and Subcutaneous
  • 4.3.2: European Systemic Lupus Erythematosus Market by End Use: Retail Pharmacies, Hospitals, Online Pharmacies, and Others
• 4.4: APAC Systemic Lupus Erythematosus Market
  • 4.4.1: APAC Systemic Lupus Erythematosus Market by Route of Administration: Oral, Intravenous, and Subcutaneous
  • 4.4.2: APAC Systemic Lupus Erythematosus Market by End Use: Retail Pharmacies, Hospitals, Online Pharmacies, and Others
• 4.5: ROW Systemic Lupus Erythematosus Market
  • 4.5.1: ROW Systemic Lupus Erythematosus Market by Route of Administration: Oral, Intravenous, and Subcutaneous
  • 4.5.2: ROW Systemic Lupus Erythematosus Market by End Use: Retail Pharmacies, Hospitals, Online Pharmacies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Systemic Lupus Erythematosus Market by Drug Class
  • 6.1.2: Growth Opportunities for the Global Systemic Lupus Erythematosus Market by Route of Administration
  • 6.1.3: Growth Opportunities for the Global Systemic Lupus Erythematosus Market by End Use
  • 6.1.4: Growth Opportunities for the Global Systemic Lupus Erythematosus Market by Region
• 6.2: Emerging Trends in the Global Systemic Lupus Erythematosus Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Systemic Lupus Erythematosus Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Systemic Lupus Erythematosus Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Roche
• 7.2: Sanofi
• 7.3: GlaxoSmithKline
• 7.4: Pfizer
• 7.5: Bayer
• 7.6: Astra Zeneca
• 7.7: Novartis